News
Outcome Capital Named Top Life Sceneces Investement Banking Firm 2025 by Life Science Review
Outcome Capital Named Top Life Sceneces Investement Banking Firm 2025 by Life Science Review January 2025 Read the full article from Life Science Magazine...
Read MoreNews
Outcome Capital Congratulates Elios Vision on the Acquisition by Bausch + Lomb
Outcome’s strategic advisory and investment banking played a critical role in the inception, growth and success of ELIOS Vision
Read MoreNews
Key Highlights from the November 2024 Life Sciences Market Pulse by Outcome Capital
Outcome Capital, a premium advisory and investment banking firm specializing in life sciences and healthcare, has released its November 2024 issue of the Life Sciences Market Pulse. This comprehensive monthly report offers valuable insights into market trends, transaction activity, and emerging opportunities in the MedTech, biotech, diagnostics, and healthcare sectors. Below, we explore the key takeaways from this latest edition.
Read MoreNews
Sepsis Test Developers Progress on Commercialization, Market Approvals of Rapid Tests During 2024
NEW YORK – In 2024, firms in the sepsis testing space made big moves to begin or expand the commercialization of tests that could help reduce the time-to-results, while many also secured funding to compete in an increasingly crowded space.
Read MoreNews
Outcome Capital Continues to Expand with the Addition of Charles Simmons
Appointment of Charles Simmons as Managing Director continues to strengthen Outcome’s capabilities
Read MoreNews
NanoHive Medical Announces $7M Series C Financing and Change to Directors Composition
BOSTON, MA, August 5, 2024 – OrthoSpineNews – NanoHive Medical, a leader in 3D-printed titanium spinal interbody fusion devices, announces a $7M Series C Financing to...
Read MoreNews
Maxim Biomedical, Inc. Announces New Minority Investment Partner and Appoints Jonathan Maa as CEO
ROCKVILLE, Md., July 29, 2024 /PRNewswire/ — Maxim Biomedical, Inc., one of the nation’s leading end-to-end rapid diagnostic test developers and manufacturers, has received a new minority...
Read MoreNews
Dx M&A Market Remains Stagnant in H1 2024
Macroeconomic uncertainty, confusion surrounding the diagnostic regulatory landscape, and the continuing post-COVID-19 pandemic hangover have all contributed to a stagnant, quiet period for mergers and acquisitions in the in vitro diagnostics space in the first half of 2024.
Read MoreNews
TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities
TFF Pharmaceuticals, Inc. announced that the Company has engaged Outcome Capital as a strategic advisor for the purpose of evaluating potential corporate partnerships and licensing opportunities.
Read MoreNews
Demand for Digital Solutions in Healthcare Remain Strong
Companies need to have a clear, stable business model in terms of who pays for what, he notes, and it helps to establish an ongoing relationship with a payor and/or provider.
Read MoreNews
Outcome Capital Continues to Expand with the Addition of Industry Veteran Stanislav Glezer, MD MBA
Dr. Glezer’s appointment as Managing Director will strengthen Outcome’s healthcare innovation and product launch expertise. BOSTON–Outcome Capital, LLC, a highly specialized life sciences and healthcare...
Read MoreNews
Outcome Capital Expands Its Medical Device and Life Science Services Practices with the Addition of Industry Veteran Peter F. Meyer, Ph.D.
BOSTON–Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Peter F. Meyer, Ph.D. has been appointed as...
Read MoreNews
With Pipeline of Syndromic Tests, Qorvo Eyes Emergence as More Than a COVID Company
Qorvo Biotechnologies said it is closing in on the launch of its point-of-care COVID-19 and influenza test as the firm works to expand its menu beyond COVID-19 and into syndromic panels and cardiac disease tests.
Read MoreNews
Outcome Capital is happy to announce recent promotions of Thomas Busby, Nick Frame, Mike Casasanta & Carey Gallant
Please join us in congratulating them on their new roles.
Read MoreNews
Outcome Capital has won honors as the Top Life Sciences Advisory & Investment Banking Firm – 2024 per Life Sciences Magazine
Outcome Capital has won honors as the Top Life Sciences Advisory & Investment Banking Firm – 2024 per Life Sciences Magazine January 2024 Read...
Read MoreNews
Dx Experts See Demand for OTC Self-Tests, Tempered by Lack of Reimbursement
In the immediate wake of the COVID-19 pandemic, there was initial enthusiasm that over-the-counter self-administered tests would see an upshot as some believed the widespread use of antigen-based COVID-19 tests would carry over to tests for other indication.
Read MoreNews
Dx M&A Deals Decline as Industry Returns to Normal Post-COVID Boom
The diagnostics industry has finally completed its return to normal after three years of heavier dealmaking, as full-company mergers and acquisitions declined to pre-COVID-19 levels in 2023.
Read MoreNews
Outcome Capital Promotes Thomas Busby to Director to Expand Medical Device and Life Science Services Practices
BOSTON — Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Thomas F. Busby has been promoted...
Read MoreNews
Outcome Capital Announces Acquisition of Propella Therapeutics, Portfolio Company of Peterson Companies, by Astellas Pharma
Outcome Capital is a strategic advisor to Peterson Companies, majority shareholder of Propella Boston – December 28, 2023 — Outcome Capital, a highly specialized life sciences...
Read MoreNews
Outcome Capital Announces Electronic Registry Systems (ERS) Acquisition by Health Catalyst
Boston – November 8, 2023 Outcome Capital, a specialized life science advisory and investment banking firm, today announced that Electronic Registry Systems, Inc. (ERS), a...
Read MoreContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Business Continuity Plan | Privacy Policy | Regulation Best Interest
